New Once Weekly HIV Oral Regimen Shows Strong Results after 48 Weeks
January 22, 2026
A phase 2 study, published in Annals of Internal Medicine and led by Joe Eron, MD, Director of the CFAR Clinical Core, found that a new once-weekly oral HIV treatment regimen achieved virologic suppression through 48 weeks. The study evaluated the efficacy and safety of once-weekly oral islatravir plus lenacapavir...
